Drug Trial Radar · NCT03596762
A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms
Last checked: Nov 19, 2026Latest source record: Mar 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
199
Actual
Start
Nov 20, 2018
Primary completion
Nov 21, 2019
Study completion Nov 21, 2019
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- Collaborators
- Nerre Therapeutics Ltd.
- First posted
- Jul 24, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 40 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the effectiveness of BAY3427080 (NT-814), taken once a day, in the treatment of troublesome post-menopausal symptoms.
Conditions
- Menopause
- Hot Flashes
- Night Waking
Interventions
Elinzanetant (BAY3427080)Drug
BAY3427080 capsules
PlaceboDrug
Placebo capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 4Time frame: From baseline to Week 4
- Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 12Time frame: From baseline to Week 12
- Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 4Time frame: From baseline to Week 4
- Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 12Time frame: From baseline to Week 12
Locations
25 sites in 3 countries. Site status is shown where the registry gives one.
Study Site 12
Mesa, Arizona
Study Site 19
San Diego, California
Study Site 13
Aventura, Florida
Study Site 15
Lake Worth, Florida
Study Site 18
Atlanta, Georgia
Study Site 16
New Orleans, Louisiana
Study Site 10
Boston, Massachusetts
Study Site 11
Boston, Massachusetts
Study Site 17
Las Vegas, Nevada
Study Site 14
Houston, Texas
Study Site 50
Red Deer, Alberta, Canada
Study Site 51
Mission, British Columbia, Canada
Study Site 54
Guelph, Ontario, Canada
Study Site 52
Scarborough Village, Ontario, Canada
Study Site 53
Toronto, Ontario, Canada
Study Site 37
Blackpool, United Kingdom
Study Site 34
Cannock, United Kingdom
Study Site 31
Glasgow, United Kingdom
Study Site 39
Leeds, United Kingdom
Study Site 38
Liverpool, United Kingdom
Study Site 30
London, United Kingdom
Study Site 36
Manchester, United Kingdom
Study Site 33
Poole, United Kingdom
Study Site 32
Southport, United Kingdom
Study Site 35
Stockton-on-Tees, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.